Public health impact and harm reduction implications of xylazine-involved overdoses: a narrative review
Abstract Introduction Xylazine, an α2-adrenoceptor agonist sedative commonly used in veterinary medicine, is not approved for human use. Nevertheless, xylazine-involved overdose rates have surged in recent years, fueled by an increasingly toxic and synthetic illicit drug supply in North America. Met...
Saved in:
Main Author: | David T. Zhu (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Reducing the harms of xylazine: clinical approaches, research deficits, and public health context
by: Claire M. Zagorski, et al.
Published: (2023) -
"Tranq-dope" overdose and mortality: lethality induced by fentanyl and xylazine
by: Mark A. Smith, et al.
Published: (2023) -
Correction: Reducing the harms of xylazine: clinical approaches, research deficits, and public health context
by: Claire M. Zagorski, et al.
Published: (2023) -
Drug use, homelessness and health: responding to the opioid overdose crisis with housing and harm reduction services
by: Katrina Milaney, et al.
Published: (2021) -
Wastewater Surveillance for Xylazine in Kentucky
by: Chris Delcher, PhD, et al.
Published: (2024)